Page 7 - Loncode Institute News Today

Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases - Financing co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB - Developing small molecules to repair neuronal dysfunction and resolve neuroinflammation - Innovative drug discovery platform leveraging insights from novel targets and pa...

Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results News provided by Share this article Share this article - AWARE-1 clinical data validate clinical development strategy by confirming pelareoreps anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors - Preclinical studies show that pelareoreps synergistic benefits extend across multiple classes of immunotherapeutic agents,...

Oncolytics Biotech Reports 2021 First Quarter Development Highlights and Financial Results - AWARE-1 clinical data validate clinical development strategy by confirming pelareoreps anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors - Preclinical studies show that pelareoreps synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors - Phase...

 E-Mail IMAGE: The background of the illustration is a photograph taken with the electron microscope showing DNA molecules decorated with MutS molecules, scanning the DNA for errors. The lower part shows... view more  Credit: CNIO Scientists from the Genomic Integrity and Structural Biology Group led by Rafael Fernández-Leiro at the Spanish National Cancer Research Centre (CNIO) have discovered how certain proteins ensure the repair of errors introduced into the DNA during its repli...

SkylineDx, Oncode Institute and Utrecht Holdings sign license agreement for innovative algorithm RAINFOREST News provided by Share this article Share this article ROTTERDAM, Netherlands and SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Today, SkylineDx announces to have signed a license agreement with Oncode Institute and Utrecht Holdings on a shared patent covering the innovative algorithm RAINFOREST. This algorithm is based on Random Forest, a specific machine learning method, and is able to ident...

A new study showed why the United Kingdom variant of the coronavirus appears to be spreading faster than the South African strain.

Press release content from Business Wire. The AP news staff was not involved in its creation. Neogene Therapeutics Announces Ton Schumacher, Ph.D., Company Co-Founder, Awarded 2021 Jeantet-Collen Prize for Translational Medicine January 26, 2021 GMT NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Jan 26, 2021-- Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that the company�...

(1) Renowned immunologist and T cell engineering expert awarded distinguished prize for conducting fundamental translational research of substantial significance for medicine Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that the companys co-founder, Board member and Chairman of its Scientific Advisory Board, Ton Schumacher, Ph.D., has been awarded the 2021 Jeantet...

Neurent Medical Closes $25 Million Series B Funding to Advance Innovative Chronic Rhinitis Treatment Company Prepares for Commercialization of Revolutionary In-Office Therapy Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced it has closed a $25 million Series B financing. The round was led by new investor LSP, from its LSP HEF-2 fund, and co-led by Atlantic Bridge, investing from its Growth Fund IV. Fountain Healthcare...

If the results are confirmed in human trials, “this has the feel of something that could be a true genetic cure with a single injection.”